Julene Argaluza, Saioa Domingo-Echaburu, Gorka Orive, Juan Medrano, Rafael Hernandez, Unax Lertxundi
Julene Argaluza, Department of Epidemiology and Public Health, Bioaraba Health Research Institute, Vitoria-Gasteiz 01002, Spain
Saioa Domingo-Echaburu, Department of Pharmacy, Alto Deba Integrated Health Care Organization, Arrasate 20500, Spain
Gorka Orive, NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, Vitoria-Gasteiz 01006, Spain
Gorka Orive, Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain
Gorka Orive, Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz 01006, Spain
Gorka Orive, Singapore Eye Research Institute, Discovery Tower, Singapore 168751, Singapore
Juan Medrano, Department of Psychiatry, Biocruces Bizkaia Health Research Institute, Mental Health Network Research Group, Osakidetza, Portugalete 48920, Spain
Rafael Hernandez, Department of Internal Medicine, Araba Mental Health Network, Vitoria-Gasteiz 01006, Spain
Unax Lertxundi, Bioaraba Health Research Institute; Osakidetza Basque Health Service, Araba Mental Health Network, Araba Psychiatric Hospital, Pharmacy Service, Vitoria-Gasteiz 01006, Alava, Spain
Author contributions: All authors participated in the work to take public responsibility for its content, provided substantial contributions to conception and design of the manuscript, contributed to drafting the article and revising it critically for important intellectual content and provided final approval of the version that was submitted.Both Julene-Argaluza and Saioa Domingo-Echaburu contributed equally to the work.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
http://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Unax Lertxundi, PhD, Chief Pharmacist, Bioaraba Health Research Institute; Osakidetza Basque Health Service, Araba Mental Health Network, Araba Psychiatric Hospital, Pharmacy Service, Calle Alava 43, Vitoria-Gasteiz 01006, Alava, Spain.
unax.lertxundietxebarria@osakidetza.net
Received: February 23, 2021
Peer-review started: February 23, 2021
First decision: June 18, 2021
Revised: June 18, 2021
Accepted: August 31, 2021
Article in press: August 31, 2021
Published online: October 19, 2021
Processing time: 233 Days and 21.1 Hours
